iTONE Trial (exercIse Training in pulmONary hypertEnsion) Exercise Program for Pediatric PH

Pulmonary Hypertension Clinical Trial

— iTONE  

Official title:

Home Exercise Training in Pediatric Pulmonary Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05442671
• Other study ID #: 20-018168
• Secondary ID: 1K23HL150337-01A
• Status: Recruiting
• Phase: N/A
• Start date: April 3, 2024
• Est. completion date: December 31, 2026

Study information

• Verified date: May 2024
• Source: Children's Hospital of Philadelphia
• Contact: Catherine Avitabile, MD
• Phone: 215-590-4040
• Email: avitabilec[@]chop.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Children with pulmonary hypertension (PH) engage in less physical activity than their peers. This is a concern since adult data support exercise as a non-pharmacologic treatment for PH. Despite adult data, therapeutic exercise has not been widely adopted in pediatric PH. Investigators have previously demonstrated that children with PH have less skeletal muscle mass in association with worse exercise performance. Interventions to increase physical activity and skeletal muscle mass may improve exercise performance and quality of life in children with PH. This study will use wearable activity monitoring devices to promote physical activity in a 16-week pilot intervention in children and teenager with PH.

Description:

Pediatric pulmonary hypertension (PH) is a rare disease, affecting 2-16 per million children. Without treatment, pulmonary vascular disease leads to right ventricular cardiac failure and death. Survival has improved with pharmacologic advances, however, 5-year survival from diagnosis is still only about 75%. Even with increased survival, pediatric PH is a severe, chronic illness with physical and psychosocial burdens affecting the quality of life of children and families. Exercise intolerance is nearly universal and adversely affects quality of life. While exercise physiology is complex, skeletal muscle deficits and dysfunction are important factors associated with exercise intolerance in adults with PH. The contraction of the skeletal muscle pump helps increase pulmonary blood flow at the initiation of upright exercise in the normal circulation. Low skeletal muscle mass and muscle dysfunction may impair this mechanism in PH. Investigators previously demonstrated low skeletal muscle mass in association with worse exercise performance in children with PH and identified this as an intervention target. As children with PH engage in less moderate and vigorous physical activity compared to healthy peers, we hypothesize that increasing physical activity could increase skeletal muscle mass and lead to improved exercise performance.

Recent trials have demonstrated improved exercise performance and functional class in adults with PH undertaking prescribed exercise training. Pediatric data are limited to a single, small study in which exercise performance improved after a 16-week home exercise program. That intervention did not include skeletal muscle assessment, wearable activity monitors, or specified behavioral theory, as does the current proposal. The characteristics of the optimal PH exercise program are not clear as prior studies often failed to provide sufficient detail to enable reproducibility. Most programs have been hospital-based, some with additional at-home components. Duration has varied from 4-15 weeks. Programs have included aerobic, resistance, and respiratory exercise. Patient adherence has been inconsistently assessed. While wearable activity monitors have been used to assess activities of daily living of PH patients, they have not been employed in PH exercise programs. In youth, practical concerns of developmental differences, access to facilities or equipment, and parental time commitment must be considered, and home programs may be critical to avoiding missed school and work.

Newer technologic advances enable remote monitoring of physical activity in the home setting. Wearable accelerometer sensors with wireless transmission capabilities allow us to measure relevant endpoints from a patient's daily life. In this study, participants will undergo baseline assessment of muscle mass and strength, 6-minute walk test distance, and quality of life prior to a 16-week home exercise program, enriched by mobile health technology. Investigators will use a wrist-worn accelerometer paired with periodic text messages to measure activity, obtain daily downloads, and engage patients to promote adherence. Assessment of muscle mass and strength, 6-minute walk test distance, and quality of life will be repeated after the intervention. This real-time monitoring of adherence and feedback to the patient represent fundamental changes in PH treatment paradigms that can significantly enhance efficacy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 18 Years

Eligibility

Inclusion Criteria:

• Age 8-18 years

• PH World Health Organization (WHO) diagnostic groups 1, 2, 3, or 4 (pulmonary arterial hypertension, PH due to left heart disease, PH due to lung disease, chronic thromboembolic PH)

• WHO functional class I or II

• Ambulatory status

• Mean pulmonary to systemic arterial pressure ratio <0.75 on most recent cardiac catheterization

• Completion of a cardiopulmonary exercise (CPET) test within 3 months

• Stable PH medication regimen for 3 months prior to the intervention

• Home Wifi connection

• Mobile device in family capable of receiving text messages

Exclusion Criteria:

• WHO functional class III or IV

• Single ventricle physiology

• Moderate to severe renal disease (>stage 3)

• Severe hepatic impairment [aspartate aminotransferase (AST)/alanine transaminase (ALT) > 2x upper limit of normal]

• Current pregnancy

• Significant developmental delay/inability to comply with verbal instructions to complete the study procedures

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Pulmonary
• Pulmonary Hypertension

Intervention

Behavioral:
• Exercise intervention
16-week home exercise intervention, enriched by mobile health technology

Locations

Country	Name	City	State
United States	Children's Hospital of Philadelphia	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Children's Hospital of Philadelphia	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in moderate to vigorous physical activity (MVPA)	Change in MVPA (min/day) will be measured by smartwatch accelerometer from baseline over the course of the intervention	Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention)
Secondary	Change in leg lean mass Z-score (LLMZ)	LLMZ will be measured by densitometry. LLMZ is a percentile score with scores -2 to 2 considered typical	Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention)
Secondary	Change in muscle strength	Upper extremity strength will be measured by handgrip dynamometer. Lower extremity strength will be measured by Biodex across the knee and ankle	Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention)
Secondary	Change in 6-minute walk test distance	6-minute walk distance (in meters) will be measured per standard American Thoracic Society guidelines	Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention)
Secondary	Change in quality of life score	Score measured by completion of PedsQL questionnaire. Scores range from 0-100 with higher scores indicating better quality of life	Pre-exercise intervention and Post intervention (within 2 weeks of completion of the 16-week exercise intervention)